issue

Dec 20, 2019

Volume 15 Number 12

This issue looks at MR severity as a predictor of therapeutic benefit in TMVI using the Tendyne system; the impact of elevated tricuspid valve inflow gradients after TTVR; TAVI vs SAVR in low surgical risk patients; the ANGIOLITE trial, a first-in-man comparison of the Angiolite SES with an EES in CAD; and an examination of stent thrombosis after endovascular revascularisation of the superficial femoral artery.

Editorial

The role of the Heart Team in the planning of aortic valve replacement
Costa G, Fukutomi M, Søndergaard L
10.4244/EIJV15I12A191
free
GLOBAL LEADERS: looking now at the bigger picture
Guedeney P, Montalescot G
10.4244/EIJV15I12A192
free
Predicting TMVR outcomes – the Tendyne experience
Piazza N, Overtchouk P, Ben-Shoshan J
10.4244/EIJV15I12A193
free

Perspectives

Interventions for valvular disease and heart failure

Clinical impact of elevated tricuspid valve inflow gradients after transcatheter edge-to-edge tricuspid valve repair
Orban M, Orban M, Braun D, Deseive S, Kupka D, Stocker TJ, Bagaev E, Karam N, Hagl C, Massberg S, Näbauer M, Hausleiter J
10.4244/EIJ-D-19-00237
free
Mitral regurgitation severity predicts one-year therapeutic benefit of Tendyne transcatheter mitral valve implantation
Badhwar V, Sorajja P, Duncan A, Thourani V, Schaefer U, Grayburn P, Dumonteil N, Babaliaros V, Garatti A, Lessick J, Chuang M, Blanke P, Muller DW
10.4244/EIJ-D-19-00333
free
Will the Evolut Low Risk trial change my practice?
O'Sullivan C, Reardon MJ, Søndergaard L, Treede H, Jüni P, Windecker S
10.4244/EIJ-D-19-00587
free
Will the PARTNER 3 Low Risk Trial change my practice?
McConkey H, Modine T, Latib A, Jüni P, Windecker S, Leon MB
10.4244/EIJ-D-19-00847
free

Coronary interventions

First-in-man randomised comparison of the Angiolite durable fluoroacrylate polymer-based sirolimus-eluting stent versus a durable fluoropolymer-based everolimus-eluting stent in patients with coronary artery disease: the ANGIOLITE trial
Moreu J, Moreno-Gómez R, Perez de Prado A, García del Blanco B, Trillo R, Pinar E, Molina E, Zueco J, Merchán A, Díaz-Fernández J, Amat-Santos I
10.4244/EIJ-D-19-00206
free
Patient-oriented composite endpoints and net adverse clinical events with ticagrelor monotherapy following percutaneous coronary intervention: insights from the randomised GLOBAL LEADERS trial
Serruys PW, Tomaniak M, Chichareon P, Modolo R, Kogame N, Takahashi K, Chang C, Spitzer E, Walsh S, Adlam D, Hildick-Smith D, Édes I, van de Harst P, Krackhardt F, Tijssen J, Rademaker-Havinga T, Garg S, Steg G, Hamm C, Jüni P, Vranckx P, Onuma Y, Verheugt F
10.4244/EIJ-D-19-00202
free
Effect of rosuvastatin and eicosapentaenoic acid on neoatherosclerosis: the LINK-IT Trial
Kuroda K, Otake H, Shinohara M, Kuroda M, Tsuda S, Toba T, Nagano Y, Toh R, Ishida T, Shinke T, Hirata K
10.4244/EIJ-D-18-01073
free

Peripheral interventions

Incidence and predictors of stent thrombosis after endovascular revascularisation of the superficial femoral artery
Bradaric C, Koppara T, Müller A, Haller B, Ott I, Cassese S, Fusaro M, Kastrati A, Laugwitz K, Ibrahim T
10.4244/EIJ-D-19-00187
free

Receive our newsletter

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 7.6
2023 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2024)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2024 Europa Group - All rights reserved